Publication:
Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data

Simple item page
dc.contributor.authorSALMAN, ANDAÇ
dc.contributor.authorsSalman, Andac; Aktas, Meryem; Sengun, Ozlem Apti
dc.date.accessioned2022-03-12T22:55:13Z
dc.date.available2022-03-12T22:55:13Z
dc.date.issued2021
dc.description.abstractOmalizumab is a well-established treatment option in chronic spontaneous urticaria unresponsive to antihistamines at standard or higher doses. However, characteristics of the remission and relapse following the withdrawal of omalizumab remain largely unknown. We aimed to define the characteristics of remission in CSU following omalizumab with gradually lengthened dosing intervals in this retrospective study of 102 patients who were treated with at least 5 doses of omalizumab between 2015 and 2020. Of 102 patients, 70 (68.6%) showed a CR to omalizumab at standard doses. Omalizumab could be discontinued in 47 of 70 patients using gradually lengthened dosing intervals. Following a mean follow-up duration of 12.2 months, 25 (58.1%) patients were still in remission while 18 (41.9%) had relapse (Follow-up data were not available in 4 patients). The relapses were unresponsive to antihistamines in 14 patients (77.7%), however, retreatment with omalizumab led to complete control of symptoms. The patients younger than 40 were more likely to relapse. Despite the need for comparison with fixed-dosing intervals in larger, prospective studies, the results of this study imply that omalizumab with gradually extended dosing intervals might provide a long duration of remission in CSU.
dc.identifier.doi10.1111/ajd.13656
dc.identifier.eissn1440-0960
dc.identifier.issn0004-8380
dc.identifier.pubmed34156714
dc.identifier.urihttps://hdl.handle.net/11424/236685
dc.identifier.wosWOS:000664186200001
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofAUSTRALASIAN JOURNAL OF DERMATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectchronic spontaneous urticarial
dc.subjectomalizumab
dc.subjectrecurrence
dc.subjectremission
dc.titleRemission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data
dc.typearticle
dspace.entity.typePublication
local.avesis.idd5eb5780-1913-4179-839a-0209a3cf02d2
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages5
oaire.citation.endPage402
oaire.citation.issue3
oaire.citation.startPage398
oaire.citation.titleAUSTRALASIAN JOURNAL OF DERMATOLOGY
oaire.citation.volume62
relation.isAuthorOfPublication22ba329a-4b06-4eb1-8549-b8b32f2d766b
relation.isAuthorOfPublication.latestForDiscovery22ba329a-4b06-4eb1-8549-b8b32f2d766b

Files

Collections

Research Outputs